Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HQP8361
- Development stage
- Phase 1
- Lead developer
- Guangzhou Shunjian Biopharmaceutical Technology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HQP8361 is an orally bioavailable small molecule inhibitor of the c-Met (hepatocyte growth factor receptor) tyrosine kinase. Originally developed as MK-8033 by Schering-Plough (now Merck & Co.), the compound was subsequently developed by Ascentage Pharma through its subsidiary, Guangzhou Shunjian Biopharmaceutical. HQP8361 targets the HGF/c-Met signaling pathway, which plays a critical role in tumor cell growth, invasion, and angiogenesis when overexpressed or mutated. It also exhibits inhibitory activity against the RON (macrophage-stimulating protein receptor) tyrosine kinase. The drug has been investigated in Phase 1 clinical trials for patients with advanced or metastatic solid tumors who have failed standard therapies.
- Brand names
- Ketai Tong'an
- Other names
- 1001917-37-83-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-N-(2-pyridinylmethyl)-5H-benzo[4,5]cyclohepta[1,2-b]pyridine-7-methanesulfonamideUNII-350H6PBQ5QUNII350H6PBQ5QUNII 350H6PBQ5Q
02
Targets
MST1R (Recepteur d'origine nantais)MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on HQP8361.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HQP8361.